Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -155.20M | -148.97M | -206.81M | -208.93M | -208.02M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.12M | -20.03M | 41.10M | 47.65M | 55.14M |
| Change in Net Operating Assets | -5.93M | 7.13M | 11.54M | -8.58M | -4.53M |
| Cash from Operations | -169.25M | -161.87M | -154.18M | -169.86M | -157.41M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 0.00 | 7.00M | 7.00M | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -143.48M | -73.61M | -55.87M | -248.38M | -353.29M |
| Cash from Investing | -143.48M | -66.61M | -48.87M | -248.38M | -353.29M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 314.44M | 227.49M | 240.07M | 239.84M | 243.89M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 0.00 | 169.21M |
| Repurchase of Preferred Stock | -- | -- | -220.00K | -355.00K | -355.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5.41M | -5.67M | -616.00K | -616.00K | -1.84M |
| Cash from Financing | 309.03M | 221.81M | 239.24M | 238.87M | 410.91M |
| Foreign Exchange rate Adjustments | -- | -15.00K | 1.00K | 1.00K | -3.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.70M | -6.68M | 36.19M | -179.38M | -99.79M |